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OBJECTIVE
Weevaluated the incidence of acute pancreatitis and pancreatic cancer in patients
with type 2 diabetes and cardiovascular disease who were treated with
sitagliptin, a dipeptidyl peptidase-4 inhibitor (DPP-4i).
RESEARCH DESIGN AND METHODS
In the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) study, a
cardiovascular safety study of sitagliptin, all suspected cases of acute pancreatitis
and pancreatic cancer were collected prospectively for 14,671 participants
during a median follow-up time of 3 years, and were adjudicated blindly.
RESULTS
Baseline differences were minimal between participants confirmed to have no
pancreatic events, acute pancreatitis, or pancreatic cancer. Among those partic-
ipants randomized to receive sitagliptin, 23 (0.3%) (vs. 12 randomized to receive
placebo [0.2%]) had pancreatitis (hazard ratio 1.93 [95% CI 0.96–3.88], P = 0.065;
0.107 vs. 0.056/100 patient-years), with 25 versus 17 events, respectively. Severe
pancreatitis (two fatal) occurred in four individuals allocated to receive sitagliptin.
Cases of pancreatic cancer were numerically fewer with sitagliptin (9 [0.1%])
versus placebo (14 [0.2%]) (hazard ratio 0.66 [95% CI 0.28–1.51], P = 0.32; 0.042
vs. 0.066 events/100 patient-years). Meta-analysis with two other DPP-4i cardio-
vascular outcome studies showed an increased risk for acute pancreatitis (risk
ratio 1.78 [95% CI 1.13–2.81], P = 0.01) and no significant effect for pancreatic
cancer (risk ratio 0.54 [95% CI 0.28–1.04], P = 0.07).
CONCLUSIONS
Pancreatitis and pancreatic cancer were uncommon events with rates that were
not statistically significantly different between the sitagliptin and placebo groups,
although numerically more sitagliptin participants developed pancreatitis and
fewer developed pancreatic cancer. Meta-analysis suggests a small absolute in-
creased risk for pancreatitis with DPP-4i therapy.
Increased risks of pancreatitis and pancreatic carcinoma are linked to type 2 di-
abetes, obesity, and insulin resistance in epidemiological studies and animal models
(1). Dipeptidyl peptidase-4 inhibitors (DPP-4is) have become widely adopted as
effective and well-tolerated glucose-lowering agents since the introduction of sita-
gliptin in 2006 (2). A potential association between DPP-4i treatment and pancre-
atitis and pancreatic cancer was suggested in 2009, based on studies in rats carrying
the human islet amyloid polypeptide transgene treated with sitagliptin, in which
increased pancreatic ductal turnover, ductal metaplasia, and isolated pancreatitis
were observed (3). Although subsequent preclinical studies have not confirmed this
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finding (4,5), this potential association
has triggered intense interest and clinical
assessment. Pharmacovigilance efforts,
epidemiological studies, andmeta-analysis
of randomized control studies with DPP-
4is have suggested a small increase in or
no increased risk of pancreatitis (6) or pan-
creatic cancer (7), but they all have meth-
odological limitations.
The Trial Evaluating Cardiovascular
Outcomes with Sitagliptin (TECOS) as-
sessed the long-term cardiovascular
safety of adding sitagliptin to usual
care, compared with usual care alone,
in patients with type 2 diabetes and es-
tablished cardiovascular disease during
a 3-year median follow-up period (8).
We describe the presentation, features,
and incidence of pancreatitis and pan-
creatic cancer cases confirmed in TECOS,
and perform a meta-analysis of these
events with two recently reported DPP-4i
cardiovascular safety trials, the Saxagliptin
Assessment of Vascular Outcomes Re-
corded inPatientswithDiabetesMellitusd
Thrombolysis in Myocardial Infarction
(SAVOR-TIMI) 53 trial (9,10) and the Ex-
amination of Cardiovascular Outcomes
with Alogliptin versus Standard of Care
(EXAMINE) trial (11).
RESEARCH DESIGN AND METHODS
The TECOS study (Clinical trial reg. no.
NCT00790205, clinicaltrials.gov) ratio-
nale and design (12) as well as its pri-
mary outcomes and safety measures
(6) have been reported previously.
Briefly, 14,735 participants from 38
countries were enrolled in the study be-
tween December 2008 and July 2012.
Eligible participants were $50 years
old with type 2 diabetes, cardiovascular
disease, and HbA1c values of 6.5–8.0%
(48–64 mmol/mol), and on stable-dose
monotherapy or dual-combination ther-
apy with metformin, pioglitazone, or
sulfonylurea, or insulin with or without
metformin. Study subjects were ran-
domized double-blind to sitagliptin or
placebo at dosing appropriate for their
estimated glomerular filtration rate.
Patients with an estimated glomerular
filtration rate of ,30 mL/min/1.73 m2
were not eligible for enrollment. Pa-
tients with a history of pancreatitis
were not excluded from the study.
Treatment for type 2 diabetes and its
comorbidities was provided by usual
care providers based on local guidelines.
The addition of any antihyperglycemic
agents, other than a glucagon-like pep-
tide 1 receptor agonist or an open-label
DPP-4i, was permitted, but rosiglitazone
use was discouraged. The intent-to-treat
(ITT) population comprised 14,671 partic-
ipants with a median follow-up period of
3.0 years (interquartile range 2.3–3.8,
maximum 5.7). Overall, 95.1% of partici-
pants allocated to receive sitagliptin and
94.1% allocated to receive placebo com-
pleted the study, with premature study
medication discontinuation occurring in
26.1% and 27.5% of participants, respec-
tively. Vital status was determined at
study end for 97.5% of participants. The
study was managed and all data were ad-
judicated and analyzed by academic part-
ners (Duke Clinical Research Institute and




A Clinical Events Committee (CEC) adju-
dicated all cases of pancreatitis and can-
cer reported by investigators, recorded
as adverse events, or identified in source
documentation for other events. The
CEC was independent of both the spon-
sor and the TECOS Executive Commit-
tee, and remained blinded to study
treatment assignment. Information re-
lated to pancreatitis events was collected
systematically in the trial database, in-
cluding relevant symptoms, laboratory
and imaging data, concomitant medica-
tion usage, and the investigator’s sus-
pected etiology of the event. Relevant
hospital and clinic records as well as lab-
oratory and imaging reports were also re-
quested for CEC review. All such cases
were first reviewed by a gastroenterol-
ogist and then forwarded to the CEC for
a second phase of independent review
and finalization of adjudication. To con-
firm a diagnosis of acute pancreatitis,
medical records or a clinical narrative pre-
pared by the study sites had to document
symptoms (abdominal pain or vomiting)
and objective evidence of pancreatic in-
flammationdeither elevated pancreatic
enzymes (amylase or lipase more than
three times the upper limit of normal for
the assay or in patients with chronic pan-
creatitis, enzyme elevations more than
two times the upper limit of normal) or
evidence of pancreatitis documented by
imaging (abdominal computed tomogra-
phy, magnetic resonance imaging, or ultra-
sound showingdiffuse and inhomogeneous
gland enlargement) (see Supplementary
Data). Confirmed cases were further char-
acterized as either “severe,” if there was
evidence of organ failure (i.e., systolic blood
pressure ,90 mmHg, partial pressure of
oxygen in arterial blood,60mmHg, serum
creatinine level .2 mg/dL after rehydra-
tion, or estimated gastrointestinal blood
loss of.500 mL in 24 h) or local complica-
tions demonstrated on imaging (i.e.,
pancreatic necrosis, abscess, or acute
pseudocyst), or “mild” (8).
Table 1—Confirmed pancreatitis and pancreatic cancer events in the TECOS Study
Patients Events
Sitagliptin (n = 7,332) Placebo (n = 7,339) HR (95% CI) P Sitagliptin Placebo
ITT analysis
Acute pancreatitis 23 (0.107) 12 (0.056) 1.93 (0.96–3.88) 0.065 25 (0.113) 17 (0.077)
Severe 4 0 4 0
Mild 19 11 21 16
Unknown 0 1 0 1
Pancreatic cancer 9 (0.042) 14 (0.066) 0.66 (0.28–1.51) 0.32
Per-protocol analysis
Acute pancreatitis 20 (0.104) 11 (0.058) 1.80 (0.86–3.76) 0.12 21 (0.109) 12 (0.063)
Pancreatic cancer 9 (0.047) 10 (0.054) 0.91 (0.37–2.25) 0.85 . . . . . .
Data are n (events per 100 patient-years of follow-up) or n, except where indicated. Some patients had more than 1 event.
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Information related to malignant/
neoplastic events was also collected sys-
tematically in the trial database. Investi-
gators reported classification (malignancy
vs. benign neoplasm), primary site, type,
stage, and extent, as well as the date of
onset and whether the malignancy/
neoplasm was clinically evident prior
to randomization. Relevant hospital and
clinic records, and laboratory, imaging,
and pathology reports were requested
for CEC review. All such cases were first
reviewed by an oncologist and then for-
warded to the CEC for a second phase of
review and finalization of adjudication.
Charter-defined malignancies included
newmalignancy or first recurrence during
the study period of a previously diagnosed
malignancy. All confirmed charter-defined
malignancies were categorized by site or
type. Confirmed pancreatic cancers were
also subcategorized as pancreatic endo-
crine or exocrine tumors, or as uncertain
types of pancreatic malignancy. No pa-
tient had both pancreatitis and pancreatic
cancer confirmed during the study.
Statistical Analysis
Descriptive statistics from the adjudica-
tion process are presented to provide a
sense of the nature of these events in
the TECOS study. Definition of the per-
protocol population is provided in the
study protocol (8). Unless otherwise
stated, continuous variables are sum-
marized as the median (interquartile
range), and categorical variables are cat-
egorized as number (percentage). The
baseline characteristics of patients in
whom pancreatitis, pancreatic cancer,
or neither were diagnosed were com-
pared with Wilcoxon rank sum, x2, and
Fisher exact tests.
The time-to-pancreatic-event analy-
ses used Cox proportional hazards re-
gression models and are presented as
hazard ratio (95% CI). Hazard ratios
and P values for treatment effect are
provided for both the ITT and per-
protocol populations. The ITT popula-
tion includes all events regardless of
treatment compliance. The per-protocol
end points are those that occurred
before a major protocol violation in pa-
tients who took at least one dose of
study medication. Event rates are
shown as the number and as events
per 100 patient-years of follow-up.
Kaplan-Meier rates over the first 3 years
forpancreatic events areplotted separately
for the sitagliptin andplacebo groups in the
ITT population.
Meta-analyses were performed on data
fromtheSAVOR-TIMI 53 trial, the EXAMINE
trial, and the TECOS study using random-
effects models on summative data for pan-
creatitis and pancreatic cancer outcomes.
Heterogeneity among studieswas assessed
using the CochranQ test and I2 index. Odds
ratios and 95% CIs are shown with forest
plots. Comprehensive Meta Analysis ver-
sion 2.0 software (Biostat, Inc., Englewood,
NJ) was used for these analyses. Except
where noted, data were analyzed using
SAS version 9.4.
RESULTS
The ITT population comprised 14,671 in-
dividuals. Relevant baseline characteris-
tics for the 14,613 participants who
had no reported pancreatic event,
35 with confirmed pancreatitis, and
23 with confirmed pancreatic cancer
are presented in the Supplementary
Appendix (Supplementary Table 1).
Differences in baseline characteristics
among these participants were generally
minimal, but smoking history differed by
category (P = 0.015). For those with pan-
creatitis, pancreatic cancer, or no pancre-
atic event, the proportions of participants
Figure 1—Cumulative proportion of participants with confirmed acute pancreatitis (A) and
confirmed pancreatic cancer (B) by treatment group as a function of time.
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who were current smokers were 23%,
13%, and 11%, respectively. Participants
with pancreatic cancer were more likely
to have smoked previously (65%) than
those with pancreatitis (31%) or no pan-
creatic event (40%). Additionally, there
was a similar imbalance with respect to
racial distribution, particularly a lower
representation of pancreatic cancer
among Asians and perhaps an increase
in pancreatitis among blacks. The aver-
age age of those with confirmed pancre-
atic events was 66 years.
Confirmed acute pancreatitis events
are shown in Table 1. The 7,332 partici-
pants assigned to receive sitagliptin had
21,508 patient-years of follow-up,
whereas those assigned to receive placebo
had 21,325 patient-years of follow-up.
Among participants randomized to re-
ceive sitagliptin, pancreatitis developed in
23 participants (0.3% of the ITT popula-
tion, 0.107/100 patient-years) compared
with 12 participantswho received placebo
(0.2% of the ITT population, 0.056/100
patient-years; hazard ratio 1.93 [95% CI
0.96–3.88], P = 0.065), with these par-
ticipants having 25 and 17 events, respec-
tively. Four participants in the sitagliptin
group experienced a severe pancreatitis
event (two fatal events), with no severe
events in the placebo group. One pancre-
atitis event of unknown severity was re-
ported for the placebo group, with all
remaining cases adjudicated as “mild” in
severity.
Figure 1A shows the cumulative pro-
portion of participants with acute pancre-
atitis as a functionof time,with nonotable
differences between groups in event rates
during the first 9months. Through 3 years
of follow-up, there appears to be a fairly
linear rate of cases for each treatment
assignment. The median times to the di-
agnosis of acute pancreatitis were 1.42
years (interquartile range 0.80–2.66
years) and 1.44 years (interquartile range
0.54–1.94 years), respectively, in the sita-
gliptin and placebo groups.
The characteristics of the confirmed
pancreatitis events for participants allo-
cated to sitagliptin or placebo are listed
in Table 2. The majority of case patients
in both groups had symptoms, elevated
pancreatic enzyme levels, and imaging
evidence of pancreatitis. Investigators
reported a suspected cause of pancrea-
titis (alcohol, biliary disease, or a history
of pancreatitis) in 60.0% of events in
sitagliptin-treated participants compared
with 47.1% in placebo-treated partici-
pants; biliary disease and/or a history of
pancreatitis were present in 11 of 23 pa-
tients in the sitagliptin group (13 of
25 events) comparedwith2 of 12patients
in the placebo group (7 of 17 events). The
number of patients without a suspected
cause was similar in the two treatment
groups (10 and 9, respectively). Addi-
tional characteristics for the four case
patients with severe pancreatitis in the
sitagliptin group are also presented in Ta-
ble 2. The characteristics of case patients
with suspected pancreatitis referred for
adjudication but not confirmed are avail-
able in the Supplementary Appendix
(Supplementary Table 2).
Confirmed pancreatic cancer cases
are shown in Table 1 for the ITT popula-
tion with numerically fewer participants
in the sitagliptin group (N = 9, 0.1%,
0.042 events/100 patient-years) com-
pared with the placebo group (N = 14,
0.2%, 0.066 events/100 patient-years)
(hazard ratio 0.66 [95% CI 0.28–1.51],
P = 0.32). Pancreatic cancer resulted in
death in seven of the sitagliptin case
patients and nine of the placebo case
patients. The median times to the diag-
nosis of pancreatic cancer were 0.80
years (interquartile range 0.48–2.36
years) and 1.05 years (interquartile
range 0.59–1.27 years), respectively, in
the sitagliptin and placebo groups. Fig-
ure 1B shows the cumulative proportion
of participants with pancreatic cancer
as a function of time, with no notable dif-
ferences among groups in event rates
during the first 12 months.
The per-protocol analyses shown in
Table 1 excluded relatively few con-
firmed cases of pancreatitis or pancreatic
cancer but tended to move the hazard
ratios toward unity for both of these
outcomes.
Meta-analysis of the data from the
three cardiovascular outcome trials
with DPP-4i reported to date (Fig. 2)
shows a statistically significant in-
creased risk of acute pancreatitis for
DPP-4i therapy (risk ratio 1.78 [95% CI
1.13–2.81], P = 0.01) without evidence
of heterogeneity. Meta-analysis for pan-
creatic cancer showed a nonsignificant
Table 2—Characteristics of pancreatitis events among sitagliptin- and placebo-







Abdominal pain 22 (88) 17 (100)
Vomiting 11 (44) 5 (29)
Evidence of pancreatic inflammation
Elevated pancreatic enzymes 15 (60) 14 (82)
Amylase or lipase .33 upper limit of normal 13 13
In patients with chronic pancreatitis, amylase, or
lipase .23 upper limit of normal
2 1
Documented by imaging 18 (72) 7 (41)
Investigator reported pancreatitis etiology
Known or suspected etiology* 15 (60) 8 (47)
Alcohol 2 0
Biliary 9 3
History of pancreatitis 6 6
Other 1 1
Unknown† 10 (40) 9 (53)
Severity indices
Severe pancreatitis 4 (16) 0 (0)
Evidence of organ failure‡ 1 0
Local complications on imaging 4 0
Pancreatic necrosis 3 0
Pancreatic abscess 2 0
Pancreatic pseudocyst 1 0
Pancreatitis resulting in death§ 2 0
Data are n (%) or n. *Investigator reported. †Events where study drug was reported as a possible
cause are included in the category for unknown. ‡The patient with evidence of organ failure
had renal failure (serum creatinine .2 mg/dL after rehydration), pulmonary insufficiency
(PAO2,60 mmHg), and shock (systolic blood pressure,90 mmHg). §The deaths resulting from
pancreatitis occurred in one patient with a history of alcohol use and one with a known history
of chronic biliary pancreatitis.
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effect of DPP-4i (risk ratio 0.54 [95% CI
0.28–1.04], P = 0.07) without evidence
of heterogeneity.
CONCLUSIONS
The TECOS study was a global, double-
blind, placebo-controlled clinical trial
of sitagliptin in individuals $50 years of
age with type 2 diabetes and established
cardiovascular disease. The TECOS study
demonstrated, on a background of usual
care, that there was no difference be-
tween treatment groups in the rates of
major cardiovascular events, heart fail-
ure, or death from any cause. This study
examined whether there was an associ-
ation between the use of sitagliptin and
pancreatic disease.
The overall rate of confirmed acute
pancreatitis was low (0.095 events/100
patient-years)with anumerically increased
but not statistically significant risk for
acute pancreatitis with sitagliptin therapy
(0.107/100 patient-years for sitagliptin
treatment vs. 0.056/100 patient-years for
placebo treatment). The clinical presenta-
tion of acute pancreatitis with regard to
symptoms and onset during the study pe-
riod was similar in the two treatment
groups. Recurrent episodes of pancreatitis
occurred in two participants treated with
sitagliptin (both had one recurrence) and
two participants treated with placebo
(one with a single recurrence and one
with four recurrences). Cases of confirmed
severe acute pancreatitis were rare, but
numerically greater with sitagliptin treat-
ment compared with placebo treatment
(four vs. zero, including two fatal cases).
For both fatal cases, an etiology other
than study treatmentwas suspected. Pan-
creatitis is often associated with multiple
risk factors, and it is unclear towhat extent
sitagliptin contributed to the pancreatitis
in each case. That said, the finding of other
potential etiologies should not provide re-
assurance that treatment with sitagliptin
was perhaps not a contributor, as the alter-
native hypothesis would be that treatment
with sitagliptin magnifies the penetrance
of risk factors on pancreatitis develop-
ment and severity.
The per-protocol analysis of individuals
with recent or ongoing treatment with
studymedication provides a similar result
for the ITT analysis with a modestly
lower point estimate for risk and wider
CI (hazard ratio 1.80 [95% CI 0.86–3.76],
P=0.12).With the small numberof events,
it is not possible to ascribe particular risk
factors for acute pancreatitis for the pop-
ulation as a whole (see Supplementary
Appendix). Although a history of pancrea-
titis was not a TECOS exclusion criterion,
the risk of acute pancreatitis with sitaglip-
tin exposure in those participants with a
history of pancreatitis cannot be esti-
mated as this information was not re-
corded systematically at baseline.
Pancreatic cancer was also an uncom-
mon event in the TECOS study (0.054
events/100 patient-years). Numerically,
there were fewer cases of pancreatic
cancer with sitagliptin treatment than
with placebo treatment, but the differ-
ence was not statistically significant. The
per-protocol analysis for pancreatic can-
cer essentially eliminates the discrep-
ancy between arms. Although the
median 3-year follow-up period during
the TECOS study is longer than in many
other diabetes outcome trials, it is insuf-
ficient to permit a robust assessment of
the long-term risk of pancreatic cancer.
SAVOR-TIMI 53 (9) and EXAMINE (11)
are two recently reported, double-blind,
placebo-controlled, cardiovascular safety
trials of DPP-4is that evaluated saxagliptin
and alogliptin, respectively. These trials
have important differences with the
TECOS study Both the SAVOR-TIMI
53 and EXAMINE trials enrolled patients
with a wider range of HbA1c levels at di-
agnosis and a shorter duration of study
treatment exposure. The SAVOR-TIMI
53 trial used different criteria in the ad-
judication of pancreatitis, whereas the
EXAMINE trial did not adjudicate cases
of pancreatitis and reported no cases of
pancreatic cancer. These factors preclude
head-to-head comparisons of the rates
of pancreatitis and could impact on the
Figure 2—Meta-analysis of pancreatitis (A) and pancreatic cancer (B) in the SAVOR-TIMI 53 trial, the
EXAMINE trial, and the TECOS study. It is noted that the SAVOR-TIMI 53 trial used different criteria
than the TECOS study for the adjudication of pancreatitis, and that in the EXAMINE trial pancreatitis
was not adjudicated and no pancreatic cancer cases were reported. *Ref. 9; †Ref. 11.
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meta-analysis presented here, which
means that these findings should there-
fore be interpreted with caution.
The primary goal of the Tecos study
was to examine the cardiovascular
safety of sitagliptin. The trial demon-
strated unequivocal evidence for no in-
creased risk of major cardiovascular
events, heart failure, or all-cause mor-
tality. Sitagliptin was associated with
good tolerability and glycemic efficacy.
These analyses of acute pancreatitis
and pancreatic cancer from the TECOS
study, and the meta-analysis with two
other large, well-conducted studies in-
volving other members of the DPP-4i
class of drugs, provide prescribers and
patients greater precision around the
question of pancreatic safety. Although
conclusions are limited by the small
numbers of events over a limited period
of follow-up, information collected
from these double-blind, randomized,
placebo-controlled trials provide the
most robust data available currently to
quantify the risk of pancreatic out-
comes associated with DPP-4i therapy.
It may be that some cases of subclinical
pancreatitis could have been missed,
but similar findings from the three trials
suggest that there is a small increased
risk of acute pancreatitis with DPP-4i
therapy. For sitagliptin, the magnitude
of excess risk based on the results of the
TECOS study is estimated to be ;1 ad-
ditional case/1,000 patient-years, al-
though severe and fatal cases occurred
in the sitagliptin group. If this difference
had been statistically significant, the
number needed to harm would have
been 1,974 to have 1 additional affected
individual with pancreatitis. Pancreatic
cancer, a condition that is almost uni-
formly fatal, occurred in roughly half as
many participants as pancreatitis, and the
risk did not appear to be increased with
sitagliptin. Longer-term pharmacovigi-
lance andpharmacoepidemiological stud-
ies of DPP-4is will be required to provide
greater insights into the pancreatic safety
of this drug class.
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